NCT05324462 - Glycaemic Control and Other Clinical Parameters in Adult Type 2 Diabetes Patients on Basal Insulin Initiating Treatment With IDegLira in Routine Clinical Practice in Colombia | Biotech Hunter

Enrollment

175

Participants

Timeline

Start Date

March 22, 2022

Primary Completion Date

July 15, 2022

Study Completion Date

July 15, 2022

Conditions

Diabetes Mellitus, Type 2

Interventions

DRUG

IDegLira

Collecting data reported in medical records of patients with T2D, who had initiated treatment with commercially available IDegLira according to the routine clinical practice and local label at the discretion of the treating physician

Trial Locations (6)

Unknown

Novo Nordisk Investigational Site, Medellín

Novo Nordisk Investigational Site, Barranquilla

Novo Nordisk Investigational Site, Bogotá

Novo Nordisk Investigational Site, Montería

Novo Nordisk Investigational Site, Cúcuta

Novo Nordisk Investigational Site, Bucaramanga